Related Experiment Video
Updated: Nov 16, 2025
A Protocol for Transcranial Photobiomodulation Therapy in Mice
Published on: November 18, 2018
Photobiomodulation therapy in age-related macular degeneration
Justin C Muste1, Aneesha Kalur1, Amogh Iyer1
1Center for Ophthalmic Bioinformatics, Cole Eye Institute, Cleveland Clinic.
Purpose Of Review:
To review the available data supporting the use of photobiomodulation therapy (PBT) in the treatment of age-related macular degeneration (AMD).
Recent Findings:
PBT might be used in treating nonexudative AMD. Limited evidence suggests that exudative AMD may also benefit from PBT.
Summary:
The optimal device would deliver doses of 60 J/cm2 or more with a multiwavelength composition through the pupil over short treatment intervals. Safe upper limits have not been established. More studies are needed to evaluate the efficacy of PBT in treating exudative and nonexudative AMD.
